Patients, advocates and medical professionals will gather next month to discuss key topics associated with inhibitors in hemophilia. The Inhibitor Patient Education Summit will focus on joint health, treatment, pain management, reimbursement, psychosocial and other important issues. The event, sponsored by the pharmaceutical company Novo Nordisk, will be held at the Courtyard Marriott in Philadelphia, PA on November 5-6, 2005.
“The Inhibitor Patient Education Summit is a much-needed forum where individuals with hemophilia and inhibitors and care providers can interact. It is our desire to run this program on an annual basis,” said Mike Sumner, MD, senior director of clinical affairs
for Novo Nordisk.
An inhibitor can develop when individuals with hemophilia produce an antibody response to certain factor products, rendering treatment with these products ineffective. Approximately 15% to 30% of people with severe hemophilia A experience this complication. Inhibitor development in patients with severe hemophilia B is somewhat less common, occurring in about 1% to 4% of that population.
To register or to learn more about the meeting call 1-888-706-6867 or go to www.inhibitorsummits.com.